Correspondence 0000950170-24-002396 from Evoke Pharma Inc (EVOK) (CIK 0001403708)
Evoke Pharma Inc (EVOK) (CIK 0001403708)
Date: Jan. 5, 2024 · CIK: 0001403708 · Accession: 0000950170-24-002396
AI Filing Summary & Sentiment
File numbers found in text: 333-275443
Letter
Re: Evoke Pharma, Inc.
January 5, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Timothy Buchmiller
Registration Statement on Form S-1
File No. 333-275443
Ladies and Gentlemen:
As representatives of the underwriters of the proposed public offering of securities of Evoke Pharma, Inc. (the “Company”), we hereby join the Company’s request that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Tuesday, January 9, 2024, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we, as representatives of the underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advises that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of Page Intentionally Left Blank]
-1-
Very truly yours,
Craig-Hallum Capital Group LLC
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
January 5, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Timothy Buchmiller
Re: Evoke Pharma, Inc.
Registration Statement on Form S-1
File No. 333-275443
Ladies and Gentlemen:
As representatives of the underwriters of the proposed public offering of securities of Evoke Pharma, Inc. (the “Company”), we hereby join the Company’s request that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Tuesday, January 9, 2024, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we, as representatives of the underwriters, wish to advise you that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advises that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of Page Intentionally Left Blank]
-1-
Very truly yours,
Craig-Hallum Capital Group LLC
By: /s/ Rick Hartfiel
Name: Rick Hartfiel
Title: Head of Investment Banking
Laidlaw & Company (UK) Ltd.
By: /s/Hugh Regan
Name: Hugh Regan
Title: Executive Director
cc: David A. Gonyer, Evoke Pharma, Inc.
Richard A. Friedman, Sheppard, Mullin, Richter & Hampton LLP
Matthew T. Bush, Latham and Watkins LLP
-2-